MONTREAL, March 13, 2007 (PRIME NEWSWIRE) -- As a result of ongoing initiatives developed last fall, Viropro Inc. (OTCBB:VPRO) ("Viropro", the "Company") issued today a second business update on its activities.
* Fact Sheet: The Company has developed a new Corporate Fact Sheet (PDF) which shows the strategic alliances and partnerships as well as potential markets for targeted biological generic therapeutic proteins.
* Web Site: The Company's official web site was reviewed to further increase and improve the clarity and accessibility of the information. It includes more information and is more representative of the Company's progress and corporate image. The French version of the web site should be completed shortly.
* Business update: The business development program undergone last summer is progressing as planned and a few more agreements/partnerships should be announced shortly.
"The recent fluctuations in the share price do not reflect the continuous efforts deployed by the management to maximize shareholders' value," stated Dr. Jean-Marie Dupuy, President and CEO. "Since a year, the Company signed many technological, licensing and partnership agreements and 2007 is looking very promising," added Mr. Dupuy.
About Viropro Inc.
Viropro Inc. conducts operations through its subsidiary Viropro International Inc., whose Head Office is located in Montreal, Canada. Viropro is a rapidly expanding biopharmaceutical company specializing in the transfer of its technologies for industrial production of biogeneric therapeutic proteins, excluding therapeutic vaccines, for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The company's principal objective is to bring about the transfer of technology to pharmaceutical companies in emerging markets with unmet medical needs such as in South America, Asia and Africa. To expand its range of expertise in biopharmaceuticals excluding therapeutic vaccines, Viropro has concluded strategic alliances with various scientific and business partners renowned in national and international spheres. Viropro's business model rests on a strategy aimed at generating recurrent short and long-term revenues, all while maximizing the value of assets and profits of its shareholders.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements." Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.